Understanding the Market | TRANSTHERA-B opened over 6% higher after reaching a project cooperation agreement with Neurocrine to further develop NLRP3-related technologies
TRANSTHERA-B's stock price opened more than 6% higher, and as of the time of writing, it has risen 6.58% to HKD 195.9, with a trading volume of HKD 6.5627 million. The company has signed a patent transfer and research cooperation agreement with Neurocrine Biosciences to develop NLRP3 inhibitors, with a total potential value of USD 881.5 million, covering exclusive development rights and related research cooperation outside of Greater China
According to the Zhitong Finance APP, TRANSTHERA-B (02617) opened over 6% higher and as of the time of writing, it has risen 6.58% to HKD 195.9, with a transaction volume of HKD 6.5627 million.
In terms of news, on November 3rd, TRANSTHERA-B announced that Neurocrine Biosciences, Inc. (NASDAQ: NBIX) (Neurocrine) has entered into a patent transfer and research collaboration agreement with the company for the development of NLRP3 inhibitors for the treatment of various diseases (the agreement).
Under the agreement, Neurocrine is granted exclusive rights to develop, manufacture, and commercialize NLRP3 inhibitors from the TRANSTHERA NLRP3 drug platform outside of Greater China, while the company retains the rights to develop, manufacture, and commercialize NLRP3 inhibitors within Greater China (Mainland, Hong Kong, Taiwan, Macau). According to the agreement, the company will be entitled to receive an upfront payment, and based on Neurocrine's development and commercialization progress, the company may receive further milestone payments related to research and development milestones and sales milestones, with a total potential value of USD 881.5 million. The agreement further covers research collaboration between the parties to further develop NLRP3-related technologies
